Literature DB >> 16237043

Cutting edge: TRAIL deficiency accelerates hematological malignancies.

Nadeen Zerafa1, Jennifer A Westwood, Erika Cretney, Sally Mitchell, Paul Waring, Manuela Iezzi, Mark J Smyth.   

Abstract

TNF apoptosis-inducing ligand is attracting considerable interest as a potential extrinsic tumor suppressor mechanism, although previous reports have conveyed somewhat contrasting views regarding the likely importance of this pathway. In this study, we provide the first evaluation of spontaneous tumor formation over the life span of TRAIL-deficient mice. Interestingly, >25% of these mice do develop lymphoid malignancies after 500 days of life. TRAIL suppressed the initiation and development of both tumors of lymphoid and stromal origin in the context of the loss of at least one p53 allele. Specific examination of the role of TRAIL in Her2/neu oncogene-driven mammary epithelial cancer revealed no critical role for TRAIL despite the inherent TRAIL sensitivity of such mammary carcinomas. Overall, the data indicate an important function of TRAIL in controlling carcinogenesis, but suggest that further examination of this pathway in epithelial malignancies is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237043     DOI: 10.4049/jimmunol.175.9.5586

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity.

Authors:  Elenia Riddick; Shavonda Evans; Jeffrey Rousch; Ephraim Gwebu; Hirendra Nath Banerjee
Journal:  J Solid Tumors       Date:  2013-12-01

Review 2.  Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.

Authors:  Briana G Nixon; Ming O Li
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure.

Authors:  Qian Chen; Pu Wang; Qingmei Zhang; Meng Xia; Guizhong Zhang; Junxin Li; Enyun Shen; Youhai H Chen; Xiaochun Wan
Journal:  J Mol Med (Berl)       Date:  2019-06-22       Impact factor: 4.599

4.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.

Authors:  Ken H Young; Dennis D Weisenburger; Bhavana J Dave; Lynette Smith; Warren Sanger; Javeed Iqbal; Elias Campo; Jan Delabie; Randy D Gascoyne; German Ott; Lisa Rimsza; H Konrad Müller-Hermelink; Elaine S Jaffe; Andreas Rosenwald; Louis M Staudt; Wing C Chan; Timothy C Greiner
Journal:  Blood       Date:  2007-09-19       Impact factor: 22.113

5.  Type I natural killer T cells suppress tumors caused by p53 loss in mice.

Authors:  Jeremy B Swann; Adam P Uldrich; Serani van Dommelen; Janelle Sharkey; William K Murray; Dale I Godfrey; Mark J Smyth
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 7.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

Review 8.  Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?

Authors:  Anne Grosse-Wilde; Christopher J Kemp
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 9.  Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma.

Authors:  Mathijs P Bergman; Mario M D'Elios
Journal:  J Biomed Biotechnol       Date:  2010-06-22

10.  Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.

Authors:  Bérengère Vire; Stéphane de Walque; Audrey Restouin; Daniel Olive; Carine Van Lint; Yves Collette
Journal:  PLoS One       Date:  2009-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.